Dual-Targeted Bispecific Nanobody Therapy for Colorectal Cancer: Harnessing CD40LG and CLDN18 Pathways

VHH-P480 is an innovative bispecific humanized nanobody designed to target both CD40 ligand (CD40LG) and claudin 18 (CLDN18), currently in the Biological Testing stage of development. This next-generation molecule is engineered to leverage the unique properties of single-domain antibodies, enabling high specificity and selectivity toward these two clinically relevant antigens. By simultaneously engaging CD40LG and CLDN18, VHH-P480 offers a novel therapeutic strategy with the potential to address key mechanisms in colorectal cancer pathophysiology and immune regulation. Its design and mechanism underscore its potential as a transformative biologic for colorectal cancer intervention.

Licensing Opportunity

VHH-P480 is available for out-licensing and collaborative development opportunities. We welcome strategic partnerships with industry leaders and research organizations to advance this innovative bispecific nanobody toward clinical and commercial success.

Development Phase

Modality

VHH-P480 is engineered as a bispecific antibody fusion construct consisting of a fully human monoclonal IgG1 backbone that targets CD40, fused at the C-terminal heavy chain via a flexible (G4S)3 linker to a single-domain antibody against claudin 18.2, and produced in CHO-K cells. The nanobody (single-domain antibody) component endows VHH-P480 with notable structural advantages, such as reduced molecular weight and increased tissue penetration, which are particularly valuable for accessing solid tumor microenvironments typical of colorectal cancer. This innovative design enhances its stability and manufacturability, while potentially improving efficacy by enabling concurrent targeting of distinct tumor-associated and immunoregulatory antigens.

Target

CD40LG and CLDN18 are both molecular targets with distinct biological roles in tumor progression and immune modulation. CD40LG, a member of the TNF superfamily, is typically expressed on activated T cells and interacts with the CD40 receptor on antigen-presenting cells, playing a crucial part in immune activation and antitumor responses. CLDN18, a barrier-forming tight junction protein, is selectively expressed on certain epithelial cells, and aberrant CLDN18 expression is observed in various tumors, including a subset of colorectal cancers. Targeting CD40LG can modulate tumor immune evasion, while CLDN18's restricted expression profile increases tumor specificity. The strategic bispecific approach of VHH-P480, targeting both CD40LG and CLDN18, offers a unique opportunity to synergize direct tumor targeting and modulation of the tumor immune environment, reinforcing its strategic value in colorectal cancer therapy development.

Mechanism of Action

VHH-P480 acts through a dual mechanism by engaging both CD40LG and CLDN18. By binding CD40LG, VHH-P480 may inhibit signaling pathways involved in immune checkpoint regulation, thereby promoting antitumor immune responses. Concurrently, targeting CLDN18.2 enables direct recognition of tumor cells with aberrant tight junction expression, adding tumor selectivity and potential for immune-mediated cytotoxicity. This bispecific modality can disrupt immune evasion and facilitate immune cell recruitment to the tumor. The nanobody platform further allows adaptation to future formats such as antibody-drug conjugates (ADC) and other bispecific architectures, broadening the therapeutic applicability across various solid tumors beyond colorectal cancer.

Colorectal Cancer

Colorectal cancer is among the most common malignancies worldwide, with a significant burden in both incidence and mortality. Contributing factors include lifestyle, genetic predisposition, and environmental influences. Standard treatment options involve surgical resection, chemotherapy, radiotherapy, and targeted biological therapies. While these approaches have improved survival, many patients with advanced-stage disease experience recurrence and resistance, highlighting the unmet need for more effective interventions. Immune-based therapies have shown promise, yet their efficacy in colorectal cancer remains limited by the tumor microenvironment and immune escape pathways. VHH-P480 addresses these limitations by simultaneously modulating immune activation (through CD40LG) and direct tumor cell targeting (via CLDN18), presenting a compelling strategy to enhance therapeutic outcomes and fill the gap in colorectal cancer management.